New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
20:25 EDTJNJ, JNJ, JPM, JPM, GS, GS, CMA, CMA, JBHT, JBHT, CBSH, CBSH, WWW, WWW, WAFD, WAFD, WABC, WABCNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.55; JPMorgan (JPM), consensus $1.29; Goldman Sachs (GS), consensus $3.05; Comerica (CMA), consensus 76c; JB Hunt (JBHT), consensus 79c; Commerce Bancshares (CBSH), consensus 68c; Wolverine World Wide (WWW), consensus 27c; Washington Federal (WAFD), consensus 37c; Westamerica Bancorp. (WABC), consensus 58c.
News For JNJ;JPM;GS;CMA;JBHT;CBSH;WWW;WAFD;WABC From The Last 14 Days
Check below for free stories on JNJ;JPM;GS;CMA;JBHT;CBSH;WWW;WAFD;WABC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 14, 2014
15:24 EDTWWW, WAFD, CMA, WABC, GS, CBSH, JBHT, JPM, JNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:19 EDTJNJ Johnson & Johnson July 105 straddle priced for 1.6% move into Q2
14:46 EDTGSGoldman Sachs technical notes ahead of earnings
Subscribe for More Information
14:41 EDTGSGoldman Sachs July 167.5 straddle priced for 2.4% move into Q2
14:40 EDTJPMJPMorgan July 56.5 straddle priced for 2.2% move into Q2
Subscribe for More Information
14:27 EDTJNJEarnings Preview: J&J pharmaceutical sales expected to drive Q2
Johnson & Johnson (JNJ) is scheduled to report second quarter earnings before the market open on Tuesday, July 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.55 on revenue of $18.94B, according to First Call. The consensus range for EPS is $1.45-$1.61 on revenue of $18.55B-$19.30B. LAST QUARTER: Johnson & Johnson reported first quarter EPS of $1.54 against estimates of $1.48 on revenue of $18.1B against estimates of $18B. The drug maker raised its fiscal year EPS view to $5.80-$5.90 against a consensus estimate of $5.83. J&J noted a 3.2% decrease in worldwide consumer sales in Q1 but saw a 10.8% increase in worldwide pharmaceutical sales. Primary contributors to operational sales growth in Q1 pharmaceutical sales were Stelara, Invega, Sustenna/Xeplion, Prezista, Velcade and sales of new products. Pharmaceutical sales results were negatively impacted by loss of exclusivity for Aciphex, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On July 14, RBC Capital raised its Q2 estimates for Johnson & Johnson to reflect the firm's outlook for higher pharmaceutical sales by the company. The firm raised its price target on the shares to $110 from $106 and kept an Outperform rating on the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 8.5% since its last earnings report, and are trading near flat in afternoon trading.
12:24 EDTJNJJohnson & Johnson technical notes before earnings
The company is scheduled to report before market open on July 15th. The shares in the prior three months have risen by more than 8%, anticipating positive news for the current and forthcoming quarters. At the current price of $105.39, the only remaining established resistance on the daily chart is at the life high of $106.74. If the news and guidance is better than expected, a run to $110, or $115 at an extreme, would be possible. If the news fails to meet expectations or guidance is weak, support would be at $102.70, the 50-day moving average. A break below this uptrend support proxy would be a sell signal in many technical trading systems and would break an uptrend in place since early March of this year. On a sliding scale of increasingly weaker news, supports would next be at $99.96, and then at $96.87.
11:38 EDTWWWWolverine World Wide July volatility increases into Q2
Wolverine World Wide July call option implied volatility is at 84, August is at 39, December is at 31; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 results after the market close on July 15.
10:23 EDTWWWWolverine World Wide technical comments ahead of results
Subscribe for More Information
08:30 EDTJNJJohnson & Johnson should be bought on any weakness, says RBC Capital
Subscribe for More Information
08:03 EDTGSGoldman Sachs volatility increases into Q2 and outlook
Subscribe for More Information
08:01 EDTJPMJP Morgan July volatility increases into Q2 and outlook
Subscribe for More Information
07:48 EDTGSQuantum computer company D-Wave may come public, FT says
Subscribe for More Information
July 11, 2014
07:36 EDTJNJJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
07:20 EDTGS, JPMBig banks seen losing reserve release cushion, Reuters says
Releasing loan-loss reserves has helped U.S. big banks weather a period of weak loan demand and lower fee income, but Q2 results from the banks may see less benefit from the practice as loss rates and reserves near their lower limits, said Reuters. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:30 EDTWWWWolverine World Wide FY14 revenue outlook too optimistic, says Piper Jaffray
Subscribe for More Information
July 10, 2014
10:05 EDTCMAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:38 EDTCMAComerica upgraded to Buy from Neutral at Guggenheim
Guggenheim upgraded Comerica to Buy given exposure to Texas and California loan growth and asset-sensitivity. Price target raised to $58 from $54.
06:52 EDTGSGoldman gains energy marketer Golender from Barclays, Reuters says
Goldman Sachs (GS) appointed oil marketer Roy Golender as vice president of energy sales from Barclays (BCS), according to Reuters citing a company spokesman. Golender's LinkedIn profile says that while at Barclays Golender spent four years in commodity derivatives sales. Reference Link
06:21 EDTJPMJPMorgan appoints Li as new China head, Reuters says
JPMorgan Chase (JPM) said it has appointed former UBS (UBS) banker David Li as the new head of its China division to replace top China banker Fang Fang who left the firm in March, according to Reuters, citing a statement from the U.S. company. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use